Search our team at AdventHealth Research Institute
Showing 1 - 2 of 2 clinical trials matching your search
-
A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination with mFOLFIRINOX Compared with mFOLFIRINOX Alone in Patients with Advanced and Unresectable or Metastatic Pancreatic Cancer
This study is not currently enrolling.Associated Conditions: Colorectal CancerResearch Area: Clinical Cancer Research -
NCT04935359
A randomized, three-arm, double-blind, placebo-controlled, phase III study, comparing NIS793 with or without spartalizumab in combination with gemcitabine and nab-paclitaxel versus matching placebos combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
This study is not currently enrolling.Associated Conditions: Pancreatic CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC. This study...